JP Morgan Chase
CAPR icon

JP Morgan Chase’s Capricor Therapeutics CAPR Stock Holding History

JP Morgan Chase’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.54M Sell
343,613
-25,521
-7% -$680K ﹤0.01% 2722
2025
Q4 		$10.7M Buy
369,134
+179,335
+94% +$2.34M ﹤0.01% 2617
2025
Q3 		$1.37M Sell
189,799
-5,390
-3% -$39.7K ﹤0.01% 4358
2025
Q2 		$1.94M Buy
195,189
+177,764
+1,020% +$1.88M ﹤0.01% 3947
2025
Q1 		$165K Buy
17,425
+745
+4% +$10.3K ﹤0.01% 5328
2024
Q4 		$230K Sell
16,680
-39,519
-70% -$692K ﹤0.01% 5419
2024
Q3 		$855K Buy
56,199
+45,381
+419% +$224K ﹤0.01% 4568
2024
Q2 		$51.6K Sell
10,818
-80,265
-88% -$448K ﹤0.01% 5848
2024
Q1 		$618K Buy
+91,083
New +$440K ﹤0.01% 4654
2021
Q3 		– Sell
-77
Closed – – 6495
2021
Q2 		$0 Buy
+77
New +$326 ﹤0.01% 6360
2020
Q4 		– Sell
-5,607
Closed -$30K – 5645
2020
Q3 		$30K Buy
5,607
+5,600
+80,000% +$32.6K ﹤0.01% 5072
2020
Q2 		$0 Buy
+7
New +$31 ﹤0.01% 5391
2017
Q4 		– Sell
-200
Closed -$4K – 5437
2017
Q3 		$4K Hold
200
– – ﹤0.01% 4807
2017
Q2 		$2K Buy
+200
New +$3.66K ﹤0.01% 4839

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase's CAPR Position: Q1 2026 in Review

JP Morgan Chase reduced its Capricor Therapeutics (CAPR) stake by 6.9% in Q1 2026, selling an estimated $680K and leaving 343,613 shares worth $9.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

JP Morgan Chase first reported a position in CAPR in Q2 2017 and has held it in 14 quarters since. The position peaked at $10.7M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • JP Morgan Chase held 343,613 shares of Capricor Therapeutics worth $9.54M as of Q1 2026.
  • JP Morgan Chase sold 25,521 Capricor Therapeutics shares in Q1 2026, an estimated $680K.
  • Capricor Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2722 holding.
  • JP Morgan Chase first reported a position in Capricor Therapeutics in Q2 2017 and has held it in 14 quarters since.
  • JP Morgan Chase's Capricor Therapeutics position peaked at $10.7M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.